ImmuPharma (LON:IMM) Trading 34.1% Higher - Time to Buy?

Key Points

• ImmuPharma plc shares surged by 34.1% during mid-day trading, reaching a last traded price of GBX 10.81 ($0.15), significantly above its prior close of GBX 8.06 ($0.11).
• The company has reported a negative PE ratio of -1,214.61 and a net margin of 3,519.56%, indicating challenging financial performance.
• ImmuPharma is a biopharmaceutical company specializing in peptide-based therapeutics, with its lead program targeting Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 57,593,953 shares traded hands during trading, an increase of 656% from the average session volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Price Performance

The company's fifty day simple moving average is GBX 2.38 and its 200-day simple moving average is GBX 2.70. The firm has a market capitalization of £54.02 million, a PE ratio of -1,214.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.